Short communicationPublished 30 Sep 2024
Monoclonal Antibodies in Autoimmune Disorders: Innovations and Challenges
Laboratory of Immunobiology and Immunogenetics, Postgraduate Program in Genetics and Molecular Biology (PPGBM), Brazil
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Monoclonal antibodies (mAbs) have revolutionized the treatment of autoimmune disorders, offering targeted therapies that enhance efficacy while minimizing adverse effects. This article explores recent innovations in mAb development, including advances in humanization techniques and the emergence of biosimilars, which aim to improve accessibility and affordability. We discuss key mAbs currently in clinical use, such as those targeting tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), highlighting their mechanisms of action and clinical outcomes in conditions like rheumatoid arthritis, lupus, and multiple sclerosis. Despite their success, challenges remain, including issues of long-term efficacy, immunogenicity, and the need for personalized treatment approaches. Additionally, we address the potential for novel mAb formats, such as bispecific antibodies and antibody-drug conjugates, to enhance therapeutic precision. This article aims to provide a comprehensive overview of the state-of-the-art in mAb therapy for autoimmune disorders, emphasizing the need for ongoing research to overcome existing hurdles and optimize treatment strategies for diverse patient populations.
Keywords
Subjects
Immunology & MicrobiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalImmunology: Current Research
- SubjectImmunology & Microbiology
- BylineArticles whose byline prints “Vinci Schuster”